Respiratory Institute, Cleveland Clinic, Cleveland, OH.
Medical University of South Carolina, Charleston, SC.
Chest. 2021 Nov;160(5):1959-1980. doi: 10.1016/j.chest.2021.07.003. Epub 2021 Jul 13.
Low-dose chest CT screening for lung cancer has become a standard of care in the United States, in large part because of the results of the National Lung Screening Trial (NLST). Additional evidence supporting the net benefit of low-dose chest CT screening for lung cancer, and increased experience in minimizing the potential harms, has accumulated since the prior iteration of these guidelines. Here, we update the evidence base for the benefit, harms, and implementation of low-dose chest CT screening. We use the updated evidence base to provide recommendations where the evidence allows, and statements based on experience and expert consensus where it does not.
Approved panelists reviewed previously developed key questions using the Population, Intervention, Comparator, Outcome format to address the benefit and harms of low-dose CT screening, and key areas of program implementation. A systematic literature review was conducted using MEDLINE via PubMed, Embase, and the Cochrane Library on a quarterly basis since the time of the previous guideline publication. Reference lists from relevant retrievals were searched, and additional papers were added. Retrieved references were reviewed for relevance by two panel members. The quality of the evidence was assessed for each critical or important outcome of interest using the Grading of Recommendations, Assessment, Development and Evaluation approach. Meta-analyses were performed where appropriate. Important clinical questions were addressed based on the evidence developed from the systematic literature review. Graded recommendations and ungraded statements were drafted, voted on, and revised until consensus was reached.
The systematic literature review identified 75 additional studies that informed the response to the 12 key questions that were developed. Additional clinical questions were addressed resulting in seven graded recommendations and nine ungraded consensus statements.
Evidence suggests that low-dose CT screening for lung cancer can result in a favorable balance of benefit and harms. The selection of screen-eligible individuals, the quality of imaging and image interpretation, the management of screen-detected findings, and the effectiveness of smoking cessation interventions can impact this balance.
低剂量胸部 CT 筛查肺癌在美国已成为一种标准的治疗方法,这在很大程度上是由于国家肺癌筛查试验(NLST)的结果。自前一次指南迭代以来,支持低剂量胸部 CT 筛查肺癌的净收益以及减少潜在危害的经验不断积累。在这里,我们更新了低剂量胸部 CT 筛查的收益、危害和实施的证据基础。我们利用更新后的证据基础,在有证据支持的情况下提供建议,并在没有证据的情况下根据经验和专家共识提供陈述。
经批准的小组成员使用人群、干预、比较、结局的格式审查了以前制定的关键问题,以解决低剂量 CT 筛查的收益和危害,以及计划实施的关键领域。自上次指南发布以来,每季度通过 MEDLINE 利用 PubMed、Embase 和 Cochrane 图书馆进行系统文献综述。检索到的参考文献的参考文献进行了搜索,并添加了其他论文。由两位小组成员审查检索到的参考文献的相关性。使用推荐、评估、开发和评估方法(Grading of Recommendations, Assessment, Development and Evaluation approach)评估每个关键或重要结局的证据质量。在适当的情况下进行了荟萃分析。根据系统文献综述中得出的证据解决了重要的临床问题。起草、投票和修订分级建议和非分级陈述,直到达成共识。
系统文献综述确定了 75 项额外的研究,这些研究为 12 个关键问题的回答提供了信息。提出了额外的临床问题,产生了 7 项分级建议和 9 项非分级共识陈述。
证据表明,低剂量 CT 筛查肺癌可以带来有利的收益与危害平衡。筛查合格人群的选择、成像和图像解读的质量、筛查发现的管理以及戒烟干预措施的有效性都可能影响这种平衡。